Study of Adenosine Deaminase Activity In COPD Patients

Thesis

Submitted for Partial Fulfillment of Master Degree in Chest Diseases & Tuberculosis

 ${\it By}$ Sarah Nabil Badry ${\it MB~Bch}.$

Supervised By

Prof. Taher Abd El Hamed El Nagar

Professor & Head of Chest Department Faculty of Medicine, Ain Shams University

Assist. Prof. Tamer Mohamed Ali

Assistant Professor of Chest Diseases Faculty of Medicine, Ain Shams University

> Faculty of Medicine Ain Shams University 2017



First and foremost, thanks to **ALLAH**, the most merciful and the greatest beneficent.

I would like to express my great appreciation to **Prof. Dr. Jaher Abdelhamed el Nagar**, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University; for his sincere effort, valuable advice and great confidence that she gave me throughout the whole work. His time and supreme effort are clear in every part of this work. Many thanks & gratitude for his.

I am deeply grateful to Assist. Prof. Jamer Mohamed Ali, Assistant Professor of Chest Diseases, Ain Shams University; for his great directions & continuous advice all through the work.

Sarah Nabil Badry



سورة البقرة الآية: ٣٢

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations	iv
Introduction	1
Aim of the Work	8
Review of Literature	
 Chronic Obstructive Pulmonary Disease (COP) 	D)9
Adenosine Deaminase (ADA)	42
Subjects and Methods	66
Results	72
Discussion	91
Summary and Conclusion	100
Recommendation	102
References	103
Arabic summary	

List of Tables

Table N	o. Title	Page No.
Table (1):	Spirometric classification of the severity of c obstructive pulmonary disease	
Table (2):	Modified medical research council dyspnea so	eale 27
Table (3):	Demographic Characteristics among the popul	lation 72
Table (4):	Simple Spirometric parameters among the spopulation	
Table (5):	Difference in comorbidities among the popula	tion 80
Table (6):	Difference in serum ADA, CRP amon population	-
Table (7):	Correlation between serum ADA and the foll parameters.	_

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Cells and Mediators Involved in Pathogenesis of COPD	
Figure (2):	Distribution of age among the popular	
Figure (3):	Distribution of weight among	
	population.	
Figure (4):	Distribution of height among	
	population	74
Figure (5):	Distribution of BMI among	
T 1 (0)	population.	75
Figure (6):	Difference in FEV 1 among	the
Figure (7).	populationDifference in FVC among the popula	
Figure (7): Figure (8):	Difference in FEV 1/ FVC among	
rigure (o).	population	,
Figure (9):	Difference in FEF 25 - 75 among	
118010 (0)	population	-
Figure (10):	Difference in comorbidities among	
	population	80
Figure (11):	Difference in serum ADA among	
	population	
Figure (12):	Difference in CRP among the popula	
Figure (13):	Negative correlation between s	
T' (1.4)	ADA and weight in group I	
Figure (14):	Negative correlation between serum	
Figure (15).	and BMI in group I Positive correlation between serum	
Figure (15):	and FEV 1 in group I	
Figure (16):	Positive correlation between serum	
1 1gui (10).	and FVC in group I.	
Figure (17):	Positive correlation between serum	
3	and FEV 1/FVC in group I	
Figure (18):	Positive correlation between serum	
-	and FEF 25 - 75 in group I	87

List of Figures cont...

Fig. No.	Title	Page No.
F: (10)		
Figure (19):	Negative correlation between	
	ADA and weight in group II.	
Figure (20) :	Negative correlation between serum	
	and BMI in group II.	88
Figure (21):	Positive correlation between serum	ADA
	and FEV 1 in group II	88
Figure (22):	Positive correlation between serum	ADA
	and FVC in group II.	88
Figure (23):	Positive correlation between serum	n ADA
	and FEV 1/FVC in group II	89
Figure (24):	Positive correlation between serum	
8 . ,	and FEF 25 - 75 in group II.	
Figure (25):	Negative correlation between	
8 • (=0)•	ADA and weight in group III	
Figure (26):	Positive correlation between serum	
1194110 (20)	and BMI in group III	
	and 21.11 111 81 out 111	

List of Abbreviations

Abb.

Full term

AECOPD Acute exacerbation of COPD CAP...... Community acquired pneumonia CLL......Chronic lymphocytic leukemia COPD...... Chronic obstructive pulmonary disease CRP...... C-reactive protein CRT..... Chemoradiotherapy DLCO...... Diffusion capacity Hs-CRP..... High sensitivity CRP IBD..... Inflammatory bowel disease ICU Intensive care unit IL-6.....Interleukin -6 LAMAs...... Long acting muscarinic receptor antagonists LDC..... Leukocyte differential count NHANES Third National Health And Nutrition Examination Survey NLR Neutropil – Lympocyte Ratio OSA..... Obstructive sleep apnea PCV.....Packed cell volume PLR......Platelet/lymphocyte ratio Pro-CT Pro-calcitonin TNF Tumor necrosis factor WHO......World health organization

Abstract

The natural history of chronic obstructive pulmonary disease is characterized by frequent exacerbations. Majority of the exacerbations are infectious and bacteria responsible for 30-50% of these cases. The purpose of this study was to assess the effect of COPD and smoking on the serum ADA level, it was found that serum ADA level decreased in COPD patients and healthy smoking group.

This study was carried out on 100 subjects (patients and controls). The Patients carried out from The Abbasyia Chest Hospital. subjects divided into 50 cases (control group) which contained 25 healthy smoker group and 25 healthy nonsmoker group, and 50 cases diagnosed as having COPD according the criteria of the global initiative for chronic obstructive lung disease (GOLD 2016), which contained 25 COPD patients were in stable state, 25 COPD patients were in acute exacerbation. Acute exacerbation was defined by the presence of an increase in at least two of the following symptoms.

Keywords: Obstructive sleep apnea- Leukocyte differential count-Chemoradiotherapy- Chronic obstructive pulmonary disease

Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality throughout the world. Chronic Obstructive Pulmonary Disease (COPD), a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients, According to GOLD, 2016 (*Marc et al., 2016*).

Adenosine Deaminase (also known as adenosine aminohydrolase or ADA) is an enzyme involved in purine metabolism (*Saboury et al.*, 2002).

Its primary function in humans is the development and maintenance of the immune system (Wilson et al., 1991).

ADA irreversibly deaminates adenosine, converting it to inosine by the substitution of the amino group for a keto group. Inosine can then be deribosylated (removed from ribose) by another enzyme called purine nucleoside phosphorylase (PNP), converting it to hypoxanthine. There are 2 isoforms of ADA: ADA1 and ADA2. ADA1 is found in most body cells (Wilson et al., 1991).

It was found that in Chronic Obstructive Pulmonary Disease patients the Adenosine Deaminase activity decreases



and the Adenosine level increases. Decrease of Adenosine Deaminase activity may play an important role in the formation of pulmonary injury in COPD patients (Goodarzi et al., 2010).

AIM OF THE WORK

This work aim to study the Adenosine Deaminase activity in COPD patients compared with healthy subjects.

Chapter One

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Definition:

Chronic Obstructive Pulmonary Disease (COPD), a common preventable and treatable disease; is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients. The chronic airflow limitation characteristic of COPD is caused by a mixture of small airways disease "obstructive bronchiolitis" and parenchymal destruction "emphysema", the relative contributions of which vary from person to person (GOLD, 2016).

COPD is a major cause of chronic morbidity and mortality throughout the world; many people suffer from this disease for years and die prematurely from it or due to its complications. Globally; the COPD burden is projected to increase in the coming decades because of continuous exposure to COPD risk factors and aging of the population (GOLD, 2016).

Chronic bronchitis is defined clinically as chronic productive cough for 3 months in each of 2 successive years in

a patient; in whom other causes of productive chronic cough have been excluded (Agusti, 2005).

Emphysema is defined pathologically, as the presence of permanent enlargement of the airspaces distal to the terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis (Agusti, 2005).

Frequent exacerbations can result in a decreased health related quality of life, a decrease in lung function, an increased risk of hospitalization and an increased risk of mortality (*Torzano et al.*, 2010).

Patients with COPD can experience periods of acute deterioration, which are called exacerbations. There are different definitions for an acute exacerbation of COPD (AECOPD). Generally accepted is the definition as in the guidelines of the World Health Organization, US National Heart Lung and Blood Institute and Global Initiative for Chronic Obstructive Lung Disease (GOLD), which define an exacerbation as "an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum that is beyond normal day-to-day variations, is acute in onset and may warrant a change in regular medications in a patient with COPD" (Vestbo et al., 2013).

Prevalence:

The lowest estimates of prevalence are usually those based on self-reporting of a doctor diagnosis of COPD or equivalent condition. For example; most data show that: less than 6% of the population has been told that they have COPD these estimates may have value. However; since they may most accurately reflect the burden of clinically significant disease that is of sufficient severity to require health services (*Halbert et al.*, 2006).

The third National Health And Nutrition Examination Survey (NHANES 3) a large national survey conducted in the US between 1988 and 1994; which states that the prevalence of respiratory symptoms varied markedly by smoking status (current > ex-smoker > never). Among white males, chronic cough was reported by 24% of smokers, 4.7% of ex-smokers, and 4.0% of never smokers. The prevalence of chronic cough among white women was 20.6% in smokers, 6.5% in ex-smokers, and 5.0% in never smokers, Also There was a smaller gradient in the prevalence of chronic cough by race (white > black). The prevalence of airflow limitation was lower than the prevalence of respiratory symptoms found in the same study, but both sets of data reinforce the view; that smoking is the most important determinant of COPD prevalence in developed countries (National Center for Health Statistics, 1995).